Role of Platinums in Triple-Negative Breast Cancer von Lynce, Filipa, Nunes, Raquel

Volltext

Tailoring Treatment for Patients with Inflammatory Breast Cancer von Newman, Alexandra B., Lynce, Filipa

Volltext

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer von Bardia, Aditya, Hurvitz, Sara A, Tolaney, Sara M, Loirat, Delphine, Punie, Kevin, Oliveira, Mafalda, Brufsky, Adam, Sardesai, Sagar D, Kalinsky, Kevin, Zelnak, Amelia B, Weaver, Robert, Traina, Tiffany, Dalenc, Florence, Aftimos, Philippe, Lynce, Filipa, Diab, Sami, Cortés, Javier, O’Shaughnessy, Joyce, Diéras, Véronique, Ferrario, Cristiano, Schmid, Peter, Carey, Lisa A, Gianni, Luca, Piccart, Martine J, Loibl, Sibylle, Goldenberg, David M, Hong, Quan, Olivo, Martin S, Itri, Loretta M, Rugo, Hope S

Volltext

CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities von Lynce, Filipa, Shajahan-Haq, Ayesha N., Swain, Sandra M.

Volltext

Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy von Barac, Ana, Blaes, Anne, Lynce, Filipa

Volltext

Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway von Heeke, Arielle L., Xiu, Joanne, Elliott, Andrew, Korn, W. Michael, Lynce, Filipa, Pohlmann, Paula R., Isaacs, Claudine, Swain, Sandra M., Vidal, Gregory, Schwartzberg, Lee S., Tan, Antoinette R.

Volltext

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer von Lynce, Filipa, Williams, James T., Regan, Meredith M., Bunnell, Craig A., Freedman, Rachel A., Tolaney, Sara M., Chen, Wendy Y., Mayer, Erica L., Partridge, Ann H., Winer, Eric P., Overmoyer, Beth

Volltext

Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study von Conley, Claire C., McIntyre, McKenzie, Pensak, Nicole A., Lynce, Filipa, Graham, Deena, Ismail-Khan, Roohi, Lopez, Katherine, Vadaparampil, Susan T., O’Neill, Suzanne C.

Volltext

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer von Schneider, Bryan P, Jiang, Guanglong, Ballinger, Tarah J, Shen, Fei, Chitambar, Christopher, Nanda, Rita, Falkson, Carla, Lynce, Filipa C, Gallagher, Christopher, Isaacs, Claudine, Blaya, Marcelo, Paplomata, Elisavet, Walling, Radhika, Daily, Karen, Mahtani, Reshma, Thompson, Michael A, Graham, Robert, Cooper, Maureen E, Pavlick, Dean C, Albacker, Lee A, Gregg, Jeffrey, Solzak, Jeffrey P, Chen, Yu-Hsiang, Bales, Casey L, Cantor, Erica, Hancock, Bradley A, Kassem, Nawal, Helft, Paul, O'Neil, Bert, Storniolo, Anna Maria V, Badve, Sunil, Miller, Kathy D, Radovich, Milan

Volltext

Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart... von Khoury, Katia, Lynce, Filipa, Barac, Ana, Geng, Xue, Dang, Chau, Yu, Anthony F., Smith, Karen L., Gallagher, Christopher, Pohlmann, Paula R., Nunes, Raquel, Herbolsheimer, Pia, Warren, Robert, Srichai, Monvadi B., Hofmeyer, Mark, Asch, Federico, Tan, Ming, Isaacs, Claudine, Swain, Sandra M.

Volltext

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study von Lynce, Filipa, Mainor, Candace, Donahue, Renee N., Geng, Xue, Jones, Greg, Schlam, Ilana, Wang, Hongkun, Toney, Nicole J., Jochems, Caroline, Schlom, Jeffrey, Zeck, Jay, Gallagher, Christopher, Nanda, Rita, Graham, Deena, Stringer-Reasor, Erica M., Denduluri, Neelima, Collins, Julie, Chitalia, Ami, Tiwari, Shruti, Nunes, Raquel, Kaltman, Rebecca, Khoury, Katia, Gatti-Mays, Margaret, Tarantino, Paolo, Tolaney, Sara M., Swain, Sandra M., Pohlmann, Paula, Parsons, Heather A., Isaacs, Claudine

Volltext

Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study von Lynce, Filipa, Mainor, Candace, Donahue, Renee N., Geng, Xue, Jones, Greg, Schlam, Ilana, Wang, Hongkun, Toney, Nicole J., Jochems, Caroline, Schlom, Jeffrey, Zeck, Jay, Gallagher, Christopher, Nanda, Rita, Graham, Deena, Stringer-Reasor, Erica M., Denduluri, Neelima, Collins, Julie, Chitalia, Ami, Tiwari, Shruti, Nunes, Raquel, Kaltman, Rebecca, Khoury, Katia, Gatti-Mays, Margaret, Tarantino, Paolo, Tolaney, Sara M., Swain, Sandra M., Pohlmann, Paula, Parsons, Heather A., Isaacs, Claudine

Volltext

Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer von Pernas, Sonia, Guerriero, Jennifer L., Naumenko, Sergey, Goel, Shom, Regan, Meredith M., Hu, Jiani, Harrison, Beth T., Lynce, Filipa, Lin, Nancy U., Partridge, Ann, Morikawa, Aki, Hutchinson, John, Mittendorf, Elizabeth A., Sokolov, Artem, Overmoyer, Beth

Volltext

A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aro... von Roy, Tina, Barrows, Elizabeth, Mainor, Candace, Collins, Julie, Lynce, Filipa, Isaacs, Claudine, Pohlmann, Paula R.

Volltext

Copy Number Variation in Inflammatory Breast Cancer von Hazra, Aditi, O'Hara, Andrea, Polyak, Kornelia, Nakhlis, Faina, Harrison, Beth T, Giordano, Antonio, Overmoyer, Beth, Lynce, Filipa

Volltext

Abstract ED4-3: Inflammatory Breast Cancer von Lynce, Filipa

Volltext

Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer von Khoury, Katia, Tan, Antoinette R., Elliott, Andrew, Xiu, Joanne, Gatalica, Zoran, Heeke, Arielle L., Isaacs, Claudine, Pohlmann, Paula R., Schwartzberg, Lee S., Simon, Michael, Korn, W. Michael, Swain, Sandra M., Lynce, Filipa

Volltext

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC von Wanderley, Carlos Wagner, Michaud, Daniel E, Kurmi, Kiran, Nelson, Adam, Zheng, Kelly F, Joshi, Shakchhi, Mehta, Anita, Townsend, Madeline G, Lynce, Filipa, Shapiro, Geoffrey I, Thaxton, Jessica, Haigis, Marcia, Guerriero, Jennifer L

Volltext

982 Immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC) von Nelson, Adam, Mehta, Anita, Townsend, Madeline G, Oliwa, Madisson, Zheng, Kelly F, Lee, Patrice A, Saccomano, Nicholas A, Lynce, Filipa, Tayob, Nabihah, Shapiro, Geoffrey I, Guerriero, Jennifer L

Volltext

Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer von Tarantino, Paolo, Leone, Julieta, Vallejo, Carlos T., Freedman, Rachel A., Waks, Adrienne G., Martínez-Sáez, Olga, Garrido-Castro, Ana, Lynce, Filipa, Tayob, Nabihah, Lin, Nancy U., Tolaney, Sara M., Leone, Jose P.

Volltext